Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview

• Programmed Death (PD)-1 Non-Small Cell Lung Cancer market size has reached to $27.5 billion in 2025 • Expected to grow to $41.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Growing Use Of Personalized Treatments Boosting Market Growth Due To Improved Survival And Reduced Side Effects • Market Trend: Innovation In Treatment Modalities With Accelerating Clinical Validation Of PD-1 Therapies For Non-Small Cell Lung Cancer • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) refers to a form of lung cancer where the tumor evades immune detection by exploiting the PD-1 pathway, a key immune checkpoint. PD-1 is a receptor on T cells that, when engaged by its ligands (PD-L1 or PD-L2), suppresses immune responses to prevent tissue damage. In NSCLC, tumors often overexpress PD-L1, leading to immune evasion and cancer progression. The main type of programmed death (PD)-1 non-small cell lung cancer market includes monotherapy and combination therapy. Monotherapy means using only one type of drug to treat a disease, without combining it with other treatments. It is used for various lines of therapies, which include first-line treatment, second-line, and beyond, by varied end users such as hospitals, specialty cancer centers, academic and research institutes, and others.

What Is The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Forecast?

The programmed death (pd)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $41.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel combination therapies, expansion of biomarker-driven personalized treatment, increasing adoption of mRNA vaccine-based therapies, growing investment in immuno-oncology research, rising government and private funding for cancer immunotherapy. Major trends in the forecast period include increased adoption of pd-1 monotherapy for nsclc, growth in combination therapies with chemotherapy, ctla-4 inhibitors, and vegf inhibitors, rising investment in targeted therapy and mrna vaccine research, expansion of first-line and second-line treatment options, integration of personalized medicine and biomarker testing in treatment planning.

Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation

1) By Drug Type: Monotherapy, Combination Therapy 2) By Line of Therapy: First-line Treatment, Second-line And Beyond 3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users Subsegments: 1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types 2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Is The Driver Of The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The increasing adoption of personalized treatments is expected to propel the growth of the programmed death (PD)-1 non-small cell lung cancer market forward. Personalized treatments refer to medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is due to the growing availability of genomic profiling and biomarker testing, as these technologies help identify specific mutations and biological markers, allowing clinicians to select therapies that are more likely to be effective for each individual. Personalized treatments help programmed death (PD)-1 non-small cell lung cancer (NSCLC) by tailoring therapies based on a patient’s genetic profile, tumor characteristics, and immune response. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 compared to 6 in the year 2022. Therefore, the increasing adoption of personalized treatments is driving the growth of the programmed death (PD)-1 non-small cell lung cancer industry.

Key Players In The Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Trends and Insights

Major companies operating in the programmed death (PD)-1 non-small cell lung cancer market are focusing on conducting clinical trials of innovative therapies, such as monotherapy, to improve outcomes for patients. Monotherapy is a treatment approach that uses a single drug or therapy to treat a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, announced positive results from its Phase III HARMONi-2 trial evaluating Ivonescimab (AK112) in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer (NSCLC). The study met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, highlighting the dual-targeted bispecific antibody's therapeutic potential.

What Are Latest Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed amount. Through this acquisition, BioNTech gained access to Biotheus’s lead asset, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, currently in late-stage clinical trials for non-small cell lung cancer and other solid tumors. Biotheus Inc. is a China-based provider of innovative antibody therapeutics that specializes in the development of multispecific biologics and immuno-oncology candidates for cancer treatment, including PD-1 therapies for non-small cell lung cancer (NSCLC).

Regional Insights

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?

The programmed death-1 (PD-1) non-small cell lung cancer market consists of revenues earned by entities by providing services such as clinical oncology services for immunotherapy administration, companion diagnostic testing, and comprehensive patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The programmed death-1 (PD-1) non-small cell lung cancer market also includes sales of pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Report 2026?

The programmed death (pd)-1 non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (pd)-1 non-small cell lung cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.